FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Nectar Lifesciences's FCF Yield % or its related term are showing as below:
NSE:NECLIFE'
s FCF Yield % Range Over the Past 10 Years
Min: -166.52 Med: 0 Max: 0
Current: -166.37
NSE:NECLIFE's FCF Yield % is ranked worse than 98.81% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.68
vs NSE:NECLIFE: -166.37
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nectar Lifesciences FCF Yield % Related Terms
Nectar Lifesciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nectar Lifesciences (NSE:NECLIFE) has a FCF Yield % of -166.37 as of Jul. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nectar Lifesciences and its competitors. According to the industry distribution chart, Nectar Lifesciences ranks #995 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Nectar Lifesciences' FCF Yield % too high?
Nectar Lifesciences' current FCF Yield % is -166.37. Based on the distribution chart, Nectar Lifesciences ranks #995 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #995 out of 1007 companies for FCF Yield %. This places Nectar Lifesciences in the lower half of its industry. The industry median FCF Yield % is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.68, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current FCF Yield % is -166.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.23 — trading 63.7% above its estimated fair value. The current FCF Yield % is -166.37. Nectar Lifesciences' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current FCF Yield % is -166.37 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹11.23 is trading 63.7% above its estimated GF Value™ of ₹6.86.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
FCF Yield %: -166.37
GF Value™: ₹6.86 vs. price of ₹11.23 (63.7% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
44GF Score
Get the complete analysis for NSE:NECLIFE
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
